



Springer Nature for Hospitals & Health

Alyssia Sebes



Springer Nature for Hospitals & Health

Alyssia Sebes

April 2016

SPRINGER NATURE

Content

1	Introduction Springer Nature
2	Solutions for Hospitals & Health
	Medical Speciality Collections
	Industry Sectors
3	New AdisInsight
	New AdisInsight Platform

Introduction Springer Nature

1.0

Springer Nature

Springer Nature is one of the world's leading global **research, educational and professional publishers**, home to an array of respected and trusted brands providing quality content through a range of innovative products and services.

Springer Nature is the world's largest academic book publisher, publisher of the world's most influential journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries.

Springer Nature was formed in 2015 through the **merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media.**

Springer Facts & Figures

Founded in Berlin in:

1842

eBooks published:

200.000+

English language
journals published:

2.900+



Nobel Prize
winners who have
published with

Springer:
220+

Global society
partners:

700+

Largest open access portfolio of any publisher worldwide
(includes BioMed Central)

Why choose Springer Nature?

Trusted source in helping:



Saving time because you have the right information at hand



Accelerate R&D, Product Development and Innovation



Discover the next big idea and stay ahead of competition

What Springer Nature offers

- Easy to discover content
- Trusted, targeted information
- Flexible business models
 - Custom Journal Collections
 - eBook Collections
 - Deposit Model
 - Databases
 - SpringerProtocols, SpringerMaterials
 - AdisInsight

Springer Platform



for Hospitals & Health

Sign up / Log in

English

Corporate edition



Springer Affiliates

Home • Contact Us

Speciality

Discipline

Browse by speciality

- ▶ Biomedicine
- ▶ Internal Medicine & Dermatology
- ▶ Neurology
- ▶ Nuclear Medicine
- ▶ Oncology & Hematology
- ▶ Orthopedics
- ▶ Pathology
- ▶ Pharmacology & Toxicology
- ▶ Public Health
- ▶ Surgery & Anesthesiology
- ▶ Radiology
- ▶ Urology & Gynecology

Providing hospital and health professionals with access to millions of scientific documents from **journals**, **books**, **series**, **protocols** and **reference works**.




New books and journals are available every day.

Featured Journals


Solutions for Hospitals & Health

2.0

Medical Speciality Collections





Medical Speciality Collections (1)



for Hospitals & Health

Sign up / Log in ▾ English ▾ Corporate edition ▾

Search  

Springer Affiliates

Home • Contact Us


Speciality

Discipline

Browse by speciality

- ▶ Biomedicine
- ▶ Internal Medicine & Dermatology
- ▶ Neurology
- ▶ Nuclear Medicine
- ▶ Oncology & Hematology
- ▶ Orthopedics
- ▶ Pathology
- ▶ Pharmacology & Toxicology
- ▶ Public Health
- ▶ Surgery & Anesthesiology
- ▶ Radiology
- ▶ Urology & Gynecology

Providing hospital and health professionals with access to millions of scientific documents from **journals**, **books**, **series**, **protocols** and **reference works**.



New books and journals are available every day.

Featured Journals

Footnote style text here.

Medical Speciality Collections (2)

✓ 12 Medical Speciality Collections

✓ Immediate Access to Quality Medical & Biomedical Research

- Thousands of eBooks, Journals and eReference Works on one platform
- Customized collections per medical speciality

✓ Business Models for Organizations of all Size

- Flexible, customizable purchase models and pricing for maximum ROI

Medical Speciality Collections (3)

Collection	Journals	Books
Biomedicine	360+	3080+
Internal Medicine & Dermatology	230+	1700+
Neurology	60+	490+
Nuclear Medicine	10+	140+
Oncology & Hematology	115+	1190+
Orthopedics	50+	440+
Pathology	25+	390+
Pharmacology & Toxicology	55+	500+
Public Health	100+	620+
Radiology	65+	950+
Surgery & Anesthesiology	90+	930+
Urology & Gynecology	35+	400+

Medical Speciality Collections (4) – Example: Biomedicine

- Covering all the major disciplines within biomedicine from **cancer research, human genetics, drug resistance and medical microbiology to virology, immunology and laboratory medicine.**
- More than 3080 Books
- 360 + Journals



for Hospitals & Health



Biomedicine

Results Matter. Choose Springer.

Keeping the medical, biomedical and health care communities up-to-speed with high quality, timely information

Springer's Biomedicine collection delivers the latest information for this important field of research. Including more than 3080 books and 360 journals, many of which are indexed by PubMed, the resource covers all the major disciplines within biomedicine from cancer research, human genetics, drug resistance and medical microbiology to virology, immunology and laboratory medicine.

Content Solutions

Top titles include




Cancer Research Books

- Cancer Cell Culture
- Encyclopedia of Cancer
- Notch Signaling in Embryology and Cancer




Journals

- Cancer and Metastasis Reviews (Impact Factor (IF): 7.787)
- Angiogenesis (IF: 3.972)
- Apoptosis (IF: 3.949)



Human Genetics Books

- Encyclopedia of Genetics, Genomics, Proteomics, and Informatics
- Atlas of Genetic Diagnosis and Counseling
- Recombinant Gene Expression




Journals

- Human Genetics (IF: 4.633)
- Cell and Tissue Research (IF: 3.677)
- Genes & Nutrition (IF: 3.329)
- Journal of Genetic Counseling (IF: 1.454)

Medical Speciality Collections (5) – Example: Biomedicine

Cancer Research



IF: 3.949



IF: 3.972




IF: 7.787

Springer Nature for Hospitals & Health / April 2016

Human Genetics




IF: 3.677



IF: 3.329



IF: 1.454



IF: 4.633v

Medical Speciality Collections (6) – Example: Biomedicine

Medical Microbiology



IF: 3.972




IF: 3.972

Virology




IF: 2.511



IF: 2.030

Immunology



IF: 5.379



IF: 2.894



IF: 3.382

Medical Speciality Collections (7) – Example: Biomedicine

Adis Journals Included



Medical Speciality Collections (8) – Example: Biomedicine

Associations

International Federation for Medical and Biological Engineering

American Association of Pharmaceutical Scientists

Biomedical Engineering Society


American Society for Reproductive Medicine

Cell Stress Society International

International CCN Society




Industry Sectors



Industry Sectors (1)





Industry Sectors (2)



Industry Sectors (3) – Example: Hospitals & Health

Journal Highlights

Adis



Societies that trust us:

EASD
European Association
for the Study of Diabetes



The Association of Bone and Joint Surgeons®
Disseminating Orthopaedic Knowledge




SSO Society of
Surgical
Oncology.
**THE AMERICAN SOCIETY OF
Breast Surgeons**

Industry Sectors (4) – Example: Hospitals & Health




[Watch the video](#)



4,300+ eBooks



70+ Reference works



[More information about:](#)
Bookmetrix


New AdisInsight

3.0

AdisInsight

Adis has provided critical content to support drug evaluation for more than 40 years. Adis was acquired by Springer Science + Business Media in 2012 which has served to further support the Adis global mission of providing trusted, scientifically sound data to aid in the development of safer, more effective medications.

Adis Product Management in USA and Italy responsible for strategy, product development, pricing, training, expert support



Large scientific editorial team in India responsible for content production

Team of specialists in NZ responsible for editorial governance and enhancement

Introducing the new AdisInsight platform

AdisInsight is an easy-to-use platform, based on the same design as SpringerLink, that provides scientifically-based content compiled from multiple sources to provide comprehensive and unbiased records, with clear referencing and links to original sources across publishers

AdisInsight brings together the most relevant data on the development of drugs in one easy to use database:


- **Drugs in commercial development worldwide across all therapeutic areas and throughout the entire development process**
- **Trials being performed to advance these drugs through international regulatory pathways**
- **Deals undertaken including acquisitions, joint ventures and collaborations**
- **Safety records including adverse drug reaction case reports and regulatory news**



Content written by scientists

Sources include:

- Medical journals
- Press releases
- Conference proceedings
- Company websites
- Trial registries
- Regulatory agency websites



Comprehensive, accurate, and timely profiles

- A **drug profile** tells the story of the drug from preclinical to clinical to marketed
- A **trial profile** provides the strategic details about a clinical trial
- A **deal profile** highlights the important information in a drug based agreement
- A **safety report** summarizes a published adverse event or significant safety news
- Profiles present concise **summaries of the key facts**
- Profiles are **updated** as new information becomes available

Ezetimibe/simvastatin

At a glance		Table of Contents
Originator	Merck/Schering-Plough Pharmaceuticals	At a glance
Class	Antihyperlipidaemics; Azetidines; Naphthalenes; Small molecules	Development Overview
Mechanism of Action	Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors	Introduction
Orphan Drug Status	No	Company agreements
On Fast track	No	Key development milestones
Highest Development Phases		Patent information
Marketed	Acute coronary syndromes; Hypercholesterolaemia; Hyperlipidaemia	Drug Properties & Chemical Synopsis
Discontinued	Aortic valve stenosis	Development Status
Most Recent Events		Summary Table
22 Dec 2014	Efficacy data from the phase III IMPROVE-IT trial in Acute coronary syndromes released by Merck	Commercial Information
20 Nov 2014	Efficacy and adverse events data from the phase III IMPROVE-IT trial in Acute coronary syndromes presented at the 87th Annual Scientific Sessions of the American Heart Association (13th Nov 2014)	Involved Organisations
		Brand Names
		Scientific Summary
		Adverse events
		Pharmacodynamics
		Drug interactions
		Therapeutic trials
		Development History
		References


Why choose AdisInsight?


- Integrated, easy-to-use platform reduces costs by **reducing the time** spent searching, simplifying access, and minimizing the need for training
- Highly regarded clinical and scientific content is written by scientists to provide **curated summaries** of drugs, trials, safety, and deals
- Delivery of the clinical trial landscape within each drug profile gives you **instant access to the studies** advancing the drug through global regulatory pathways
- **Faster research and greater discoveries** from a single search across drug, trial, safety, and deal content
- Applicable to **multiple groups** due to the usefulness of AdisInsight content throughout the drug lifecycle delivers high value for money across your organization

New AdisInsight Platform

The screenshot shows the AdisInsight website interface. The browser address bar displays `adis.springer.com`. The top navigation bar includes the AdisInsight logo, a search bar, and links for "Sign up / Log in" and the Springer logo. The search bar contains the text "Search:" followed by a dropdown menu. The dropdown menu is open, showing options: "by Drug Name", "by Drug Name", "by Indication", "by Mechanism", "by Drug Class", "by Adverse Event", and "All Text". The "by Drug Name" option is highlighted with an orange circle. To the right of the search bar is a blue search button with a magnifying glass icon, also circled in orange. Further right is a "Query Builder" link. On the left side of the page, there is a vertical "Feedback" button. The main content area features the heading "AdisInsight: Your window into drug development and innovation worldwide." followed by a "Training Schedule" section. Under the training schedule, there is a section titled "AdisInsight platform Intro" with a description: "This session introduces user to the new AdisInsight platform. We will cover the different types of content available, options for searching, how to refine your search results, changes to profiles, and instructions on exporting." Below this, there is a table with the following information: "02 Oct 2014", "1100 - 1200 hrs", "CET", and a "» Register" link.

← → ↻ 🏠 `adis.springer.com` ★ ☰

» Sign up / Log in 

 Search: **by Drug Name** 🔍 Query Builder

Feedback


AdisInsight: Your window into drug development and innovation worldwide.

Training Schedule


AdisInsight platform Intro


This session introduces user to the new AdisInsight platform. We will cover the different types of content available, options for searching, how to refine your search results, changes to profiles, and instructions on exporting.


02 Oct 2014	1100 - 1200 hrs	CET	» Register
-------------	-----------------	-----	------------



[» Sign up / Log in](#)



Search: by Drug Name 



Query Builder

Refine Your Search

Indication

☐ Neurological disorders

145

☐ Cardiovascular disorders

117

☐ Pain

92

☐ Arrhythmias

89

☐ CNS disorders

68

Phase

☐ Marketed

37

☐ Registered

11

☐ Preregistration

9

☐ Phase III

20

☐ Phase II/III

3

Location

☐ Europe

145

☐ North America

117

☐ Asia

92

☐ Latin America

89

☐ Africa

68

Search results for **Mechanism of Action: "Sodium channel antagonists" AND Modification Date: before "2014-10-01"**

271 Drugs

154 Deals

5,473 Safety Reports

900 Trials

Showing 50 of 271 drugs

Sort by: Update date 

Export

Research programme: sodium channel blockers - RaQualia Pharma

01 Oct 2014


Nav1.3 sodium channel inhibitors


Active Indications

Research: Inflammatory pain; Neuropathic pain

No Inactive Indications

Originator: Pfizer | Licensed by: RaQualia Pharma

Adis Insight » Sign up / Log in 


Search: by Drug Name  [Query Builder](#)

Drug Profile

Eslicarbazepine acetate

Alternative Names: Aptiom[®]; BIA 2-093; ESL; Exalief[™]; SEP-0002093; SEP-2093; Stedesa[™]; Zebinix[®]

Latest Information Update: 13 Sep 2014

 [Print Profile](#)

At a glance

Originator	Bial
Developer	BIAL; Eisai Co Ltd; Sunovion Pharmaceuticals
Class	Acetates; Amides; Analgesics; Antiepileptic drugs; Dibenzazepines; Esters; Small molecules
Mechanism of Action	Sodium channel antagonists; T type calcium channel




Table of content

At a glance

Development Overview

- Introduction
- Company agreements
- Key development milestones
- Patent information

Drug Properties & Chemical Synopsis

Development Status

- Summary Table

Commercial Information

- Involved Organisations
- Brand Names

Scientific Summary

- Pharmacokinetics
- Adverse events
- Pharmacodynamics
- Drug interactions
- Therapeutic trials

Development History

References

Search: by Indication ▼

[Query Builder](#)

Refine Your Search

Phase [see all](#)

<input type="checkbox"/> Phase IV	212
<input type="checkbox"/> Phase III/IV	1
<input type="checkbox"/> Phase III	322
<input type="checkbox"/> Phase II/III	14
<input type="checkbox"/> Phase II	406

Status [see all](#)

<input type="checkbox"/> Completed	1,020
<input type="checkbox"/> Recruiting	137
<input type="checkbox"/> Discontinued	51
<input type="checkbox"/> Active, no longer recruiting	42
<input type="checkbox"/> Not yet recruiting	31

Indication [see all](#)

<input type="checkbox"/> Asthma	1,334
<input type="checkbox"/> Hypersensitivity	1,334
<input type="checkbox"/> Immunological disorders	1,334
<input type="checkbox"/> Obstructive airway disorders	1,334
<input type="checkbox"/> Respiratory tract disorders	1,334

 Search results for **Indication:** "asthma"

1,148 Drugs

218 Deals

0 Safety Reports

1,334 Trials

Showing 50 of 1,334 trials

[Export](#)

A Multi-Centre, Randomized, Double Blind Cross-Over Study to Assess the Non-Inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma

02 Oct 2014

Completed

 Drugs: [Fluticasone furoate](#)

Indications: Asthma

Phase of Trial: Phase II

Phase I study of AXP 1275 in healthy volunteers

02 Oct 2014

Completed

 Drugs: [AXP 1275](#)

Refine Your Search

Mechanism Of Action	see all
<input type="checkbox"/> Beta 2 adrenergic receptor agonists	32
<input type="checkbox"/> Immunomodulators	28
<input type="checkbox"/> Steroid receptor agonists	25
<input type="checkbox"/> Glucocorticoid receptor agonists	17
<input type="checkbox"/> Cytokine modulators	16

Indication	see all
<input type="checkbox"/> Asthma	218
<input type="checkbox"/> Hypersensitivity	218
<input type="checkbox"/> Lung disorders	218
<input type="checkbox"/> Obstructive airway disorders	218
<input type="checkbox"/> Respiratory tract disorders	218

Organisation	see all
<input type="checkbox"/> AstraZeneca	12
<input type="checkbox"/> GlaxoSmithKline	9
<input type="checkbox"/> SkyePharma PLC	9
<input type="checkbox"/> Novartis	8
<input type="checkbox"/> Bayer	6

Search results for Indication: "asthma"

1,148 Drugs	218 Deals	0 Safety reports	1,334 Trials
-------------	-----------	------------------	--------------

Showing 50 of 218 deals

Licensing - 15 Apr 2014

Mylan – Prosonix**Drugs:** Fluticasone propionate | **Indications:** Asthma

In September 2014, Prosonix achieved milestone payment from Mylan, following the validation of its Marketing Authorisation Application (MAA) for PSX1001 and is being assessed under the Decentralised Procedure (... [See more](#))

Licensing - 30 Aug 2014

Almirall S.A. – AstraZeneca

Drugs: Abediterol; Acclidinium bromide; Acclidinium bromide/formoterol; LAS 190792 | **Indications:** Asthma; Chronic obstructive pulmonary disease

In July 2014, AstraZeneca entered into an agreement to transfer to the company the rights to Almirall's respiratory franchise for an initial consideration of \$US875 million on completion, and up to \$US1.22... [See more](#)

Licensing - 12 Jun 2014

AstraZeneca – Synairgen**Drugs:** Not related | **Indications:** Asthma; Chronic obstructive pulmonary disease

In June 2014, AstraZeneca entered into a global licence agreement with Synairgen plc for SNG001. Under the terms of the exclusive licence agreement, AstraZeneca will pay Synairgen a \$US7.25 million upfront fee... [See more](#)

Search: by Adverse Event ▼ Headache

[Query Builder](#)

Refine Your Search

Adverse Event	see all
<input type="checkbox"/> Headache	492
<input type="checkbox"/> Neurologic manifestations	492
<input type="checkbox"/> Neurological disorders	492
<input type="checkbox"/> Pain	492
<input type="checkbox"/> Signs symptoms and ill-defined conditions	213

Drug Name	see all
<input type="checkbox"/> Sildenafil	17
<input type="checkbox"/> Immune globulin	15
<input type="checkbox"/> Tacrolimus	12
<input type="checkbox"/> Ciclosporin	10
<input type="checkbox"/> Venlafaxine	10

Mechanism Of Action	see all
<input type="checkbox"/> Neurotransmitter modulators	127
<input type="checkbox"/> Immunomodulators	97
<input type="checkbox"/> Oxidoreductase modulators	57
<input type="checkbox"/> Immunosuppressants	53

 Search results for **Adverse Event:** "Headache"

1,105 Drugs

0 Deals

492 Safety Reports

0 Trials

Showing 50 of 492 safety reports

[Export](#)

Adverse event case report

01 Oct 2014

Caspofungin

Visual impairment, phlebitis and headache: 3 case reports

3
cases

Adverse Events: Headache; Phlebitis; Vision disorders

Reporter Country: China

Adverse event case report

30 Sep 2014

Omalizumab

Tiredness, headache, and malaise: 3 case reports

3
cases

Adverse Events: Fatigue; Headache; Malaise

Reporter Country: Netherlands

Adverse event case report

23 Sep 2014

Tacrolimus

Headaches: case report

1

Thank you!

Want to know more?

Come visit me at our Springer Nature booth or contact me:

Alyssia Sebes

Corporate Sales Iberia & Benelux

alyssia.sebes@springernature.com

+31 (0)6 53 29 76 72